Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA.
Mov Disord. 2010 Jan 30;25(2):224-8. doi: 10.1002/mds.22907.
Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE-HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression.
尿酸(UA)可能与帕金森病和相关神经退行性疾病的进展有关;然而,其与亨廷顿病(HD)进展的关系尚未得到探索。对 CARE-HD 临床试验的 347 名受试者进行了二次分析,以检查基线 UA 水平与 HD 功能下降水平之间的关系。结果包括在 30 个月时统一亨廷顿病评定量表各组成部分的评分变化。随着基线 UA 水平的升高,总功能能力的恶化程度随着时间的推移而降低(调整后的评分恶化:3.17、2.99、2.95、2.28、2.21,从最低到最高 UA 五分位数,P = 0.03)。这些数据表明,UA 水平较高与 HD 进展较慢之间可能存在关联,特别是用总功能能力来衡量。如果得到证实,UA 可能是影响 HD 进展速度的一个重要预测指标和潜在可改变的因素。